Prostate Cancer Studies

Select Posters

2016

Single CTC Characterization Identifies Phenotypic and Genomic Heterogeneity as a Mechanism of Resistance to AR Signaling Directed Therapies (AR Tx) in mCRPC Patients. ASCO GU 2016.

Clinical Validation of CTC Subtype Frequency to Prognosis Overall Survival (OS) in Metastatic Castrate Resistant Prostate Cancer (mCRPC) Patients. ASCO GU 2016

The Use of Whole Genome Copy Number Variation (CNV) to Measure Genomic Instability in mCRPC CTCs. ASCO GU 2016

Validation of AR-V7 as a Treatment-Specific Biomarker at Decision Points in Management of Castration-Resistant Prostate Cancer. AACR 2016

AR-V7 Status and CTC Heterogeneity Improve the Prediction of Drug Sensitivity and Patient Outcomes for Taxanes and Approved AR Targeted Therapies ASCO 2016

2015

Single cell analysis of AR N terminal, AR C terminal and the Arv7 splice variant in CTCs of metastatic castration resistant prostate cancer (mCRPC) patients. AACR 2015

Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC). ASCO 2015

Single cell genomic profiling of circulating tumor cells (CTCs) from metastatic colorectal cancer (mCRC) identify tumor heterogeneity and rare somatic driver alterations. EORTC 2015

2014

Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC). ASCO GU 2014

Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC). ASCO GU 2014

Characteristics of de novo resistance to androgen targeting therapeutics (AR Tx) through circulating tumor cells (CTCs) analysis in metastatic castration resistant prostate cancer (mCRPC) patients. ESMO 2014

Return to Posters

Return to Technical Resources

Return to Analysis by Cancer Indication